What is Organicell Regenerative Medicine, Inc. (OCEL) stock price today?

Organicell Regenerative Medicine, Inc. (OCEL) is currently trading at $2.74, down 0.27% today.

What is OCEL P/E ratio?

Organicell Regenerative Medicine, Inc.'s P/E ratio is -4.73. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is OCEL return on equity (ROE)?

Organicell Regenerative Medicine, Inc.'s return on equity (ROE) is 455.87%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is Organicell Regenerative Medicine, Inc.'s market cap?

Organicell Regenerative Medicine, Inc. has a market capitalization of $19.97M.

OTC · Biotechnology

Organicell Regenerative Medicine, Inc. (OCEL) Stock

$2.74 -0.27% OTC: OCEL Healthcare

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions.

Valuation

Metric	Value
Price	$2.74
Market Cap	$19.97M
P/E Ratio	-4.73
P/B Ratio	29.88
P/S Ratio	2.86
EPS (TTM)	$-0.86
52-Week High	$4.80
52-Week Low	$0.90
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	455.87%
ROA	-99.95%
ROCE	-532.77%
Gross Margin	81.52%
Operating Margin	-59.10%
Net Margin	-55.59%
Debt/Equity	0.13
Current Ratio	1.05

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$6.0M	$6.0M	$5.0M	$5.0M	$5.0M
Operating Profit	$-13.0M	$-9.0M	$-7.0M	$-5.0M	$-5.0M
Net Profit	$-13.0M	$-9.0M	$-7.0M	$-5.0M	$-6.0M
EPS	$-2.42	$-1.57	$-0.99	$-0.74	$-0.86
Op Margin	-227.7%	-136.2%	-148.4%	-115.1%	-103.6%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$2.0M	$6.0M	$3.0M	$2.0M	$2.0M
Total Liabilities	$5.0M	$4.0M	$4.0M	$3.0M	$3.0M
Cash	$0	$4.0M	$2.0M	$1.0M	$0
Borrowings	$1.0M	$1.0M	$1.0M	$0	$0

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-3.0M	$-3.0M	$-2.0M	$-1.0M	$-1.0M
Investing Cash Flow	$-1.0M	$-2.0M	$0	$0	$0
Financing Cash Flow	$3.0M	$8.0M	$-1.0M	$0	$0
Net Cash Flow	$0	$4.0M	$-2.0M	$-1.0M	$0
Free Cash Flow	$-3.0M	$-4.0M	$-2.0M	$-1.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.16
EV / EBITDA	236.69
FCF Yield	-6.76%
Quick Ratio	0.83
Interest Coverage	25.49
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AMHVAmerican Hemp Ventures, Inc.	$0.98	+0.00%	—	$16.47M	0.00%
ATHJFAntisense Therapeutics Limited	$0.01	-76.00%	-1.00	$19.64M	0.00%
EMMLFOKYO Pharma Limited	$0.01	+0.00%	-5.86	$22.73M	0.00%
GRAMFTPCO Holding Corp.	$0.16	-15.36%	-0.07	$20.12M	0.00%
KMSTFKadimastem Ltd	$3.21	-3.02%	-1.52	$9.50M	0.00%

About Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.

Organicell Regenerative Medicine, Inc. is headquartered in US.

Organicell Regenerative Medicine, Inc. (OCEL) stock trades at $2.74 with a market capitalization of $19.97M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.73, reflecting a net loss over the last twelve months, price-to-book of 29.88, price-to-sales of 2.86. Over the past 52 weeks the stock has ranged between $0.90 and $4.80, and currently trades 42.9% below its 52-week high.

On profitability, Organicell Regenerative Medicine, Inc. generates a return on equity (ROE) of 455.87%, above the typical market range of roughly 12-15%, return on capital employed of -532.77%, an operating margin of -59.10%, a net profit margin of -55.59%.

Official website: www.organicell.com